Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma-Reference-Cited by-同舟云学术

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

Published:2015-05-21 Issue:21 Volume:125 Page:3357-3359
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Cheah Chan Yoon¹^ORCID,Nastoupil Loretta J.¹^ORCID,Neelapu Sattva S.¹,Forbes Sheryl G.¹,Oki Yasuhiro¹,Fowler Nathan H.¹

Affiliation:

1. Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/21/3357/1386648/3357.pdf

Reference6 articles.

1. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.;Gopal;N Engl J Med,2014

2. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.;Furman;N Engl J Med,2014

3. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.;Quach;Leukemia,2010

4. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances.;So;Biochem J,2012

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review;Targeted Oncology;2024-06-19

2. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia;Expert Opinion on Drug Metabolism & Toxicology;2023-09-02

3. Marginal zone lymphoma: 2023 update on diagnosis and management;American Journal of Hematology;2023-08-21

4. Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma;JAMA Internal Medicine;2023-05-01

5. PI 3 Kinase, AKT , and m TOR Inhibitors;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15